Deciphering differential biomarkers for anti-interleukin-6 receptor and anti-tumour necrosis factor-α treatment response in rheumatoid arthritis by multiomics analysis
Authors' conclusion
The unbiased analysis of serum proteins identified biomarkers most predictive of anti-IL-6R and anti-TNF-α at different timepoints that could explain the difference in the response rate in patients with RA.
Study context
- Population
- Patients with active rheumatoid arthritis (RA) intolerant/inadequate responders to MTX804 serum samples
- Participants
- 268 patients
- Comparison
- Sarilumab (anti-IL-6R) vs adalimumab (anti-TNF-α) monotherapy: predictive and pharmacodynamic blood biomarkers
Methodological detailsdouble-blind, phase III, multiomics (Olink proteomics, RNA sequencing), Gene expression change assessed by RNA sequencing (522 peripheral blood samples from 261 patients)
- Double-blind
- Phase III
- Multiomics (Olink proteomics, RNA sequencing)
- Gene expression change assessed by RNA sequencing (522 peripheral blood samples from 261 patients)
Primary result
As reported in the abstract
baseline, week 2, week 24
- Serum biomarkers most predictive to anti-IL-6R differed from those of anti-TNF-α; anti-IL-6R predictors correlated with innate immune activation and synovial inflammation, anti-TNF-α predictors more T-cell and neutrophil-related
- Absolute prediction performance of single and combination baseline biomarkers using cross-validation was limited; focus on relative prediction
- Pharmacodynamic effects of anti-IL-6R and anti-TNF-α on biomarkers and pathway signatures were distinct
Original publication
Deciphering differential biomarkers for anti-interleukin-6 receptor and anti-tumour necrosis factor-α treatment response in rheumatoid arthritis by multiomics analysis. RMD Open. Published 4 August 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →